AXSM Q4 2024 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$9B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$119M+66.0% YoY

Gross Profit

$108M91.1% margin

Operating Income

-$73M-61.1% margin

Net Income

-$75M-63.1% margin

EPS (Diluted)

$-1.54

QoQ Revenue Growth

+13.4%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$568M

Total Liabilities

$511M

Stockholders' Equity

$57M

Cash & Equivalents

$315M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$119M	$72M	+66.0%
Gross Profit	$108M	$64M	+68.7%
Operating Income	-$73M	-$98M	+26.1%
Net Income	-$75M	-$99M	+24.1%

Revenue Segments

Product

$204M100%

Geographic Segments

UNITED STATES

$117M99%

Non-US

$1M1%